Key points are not available for this paper at this time.
Terminalia chebula is one of the promising plants well known for its broad spectrum of therapeutic values in treating various threatful diseases and disorders. T. Chebula still stands tall as the primary medication for many common health disorders due to its ability to treat many clinical pathogens effectively even today. In the present study, ethyl acetate and acetone extracts of Terminalia chebula fruit were studied for their antibacterial activity against a few clinical isolates like Staphylococcus aureus, Escherichia coli, Klebsiella pneumonia and Salmonella typhi. Antibacterial susceptibility was screened using the well diffusion method and the minimum inhibitory concentration (MIC) was determined using the Strip dip method developed as a part of this study. Positive results were observed in both the extracts of T. chebula fruits but comparatively ethyl acetate extracts showed more effective reports than the acetone extract. The highest growth inhibition with 98.77% and 98.59 % is observed by ethyl acetate extract whereas 94.25% and 91.08% were observed in acetone extract of T. chebula fruits against E. coli and K. pneumonia respectively. Further, S. aureus and S. typhi showed 87.69% and 74.40% growth inhibition with ethyl acetate extract whereas 85.89 % and 66.60% growth inhibition in acetone extract respectively at 4mg concentration. The results show that T. chebula is still importing promising results against many deadly microbes and can be an effective medicine for many upcoming pathogens.
Munuru et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: